We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$55.1M
Cap. Flow
+$73.1M
Cap. Flow %
15.11%
Top 10 Hldgs %
57.22%
Holding
53
New
11
Increased
11
Reduced
16
Closed
15
Avg Time Held Equity + Options
4.3 quarters
Top 10 Avg Time Held Equity + Options
4.3 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
4.3 quarters
Top 10 Avg Time Held Equity only
4.3 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Buys

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$43.2M
2
JANX icon
Janux Therapeutics
JANX
+$35.9M
3
NKTR icon
Nektar Therapeutics
NKTR
+$31M
4
VEEV icon
Veeva Systems
VEEV
+$23.9M
5
PHR icon
Phreesia
PHR
+$20.2M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$21.8M
2
BBIO icon
BridgeBio Pharma
BBIO
+$15.4M
3
ROIV icon
Roivant Sciences
ROIV
+$14M
4
DXCM icon
DexCom
DXCM
+$13.1M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
2 Industrials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TECX icon
26
Tectonic Therapeutic
TECX
$417M
$4.9M 1.01%
235,000
-144,254
-38% -$2.68M
2025 Q1
3 quarters
CDNA icon
27
CareDx
CDNA
$3.38B
$4.71M 0.97%
250,000
-254,030
-50% -$4.26M
2024 Q4
4 quarters
TERN icon
28
DELISTED
Terns Pharmaceuticals
TERN
$3.84M 0.79%
+95,000
New +$2.2M
2025 Q4
0 quarters
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$252M
$2.61M 0.54%
743,942
-524,023
-41% -$1.79M
2024 Q3
5 quarters
KIDS icon
30
OrthoPediatrics
KIDS
$573M
$2.43M 0.5%
136,741
-171,966
-56% -$3.01M
2025 Q2
2 quarters
OKUR icon
31
OnKure Therapeutics
OKUR
$95.2M
$2.37M 0.49%
816,909
+548,950
+205% +$1.64M
2024 Q4
4 quarters
BBIO icon
32
BridgeBio Pharma
BBIO
$12.4B
$2.29M 0.47%
30,000
-234,500
-89% -$15.4M
2024 Q1
7 quarters
ABVX icon
33
Abivax
ABVX
$7.52B
$2.29M 0.47%
+17,000
New +$1.85M
2025 Q4
0 quarters
ACET icon
34
Adicet Bio
ACET
$47.8M
$2.11M 0.44%
+250,244
New +$2.77M
2025 Q4
0 quarters
TEM icon
35
Tempus AI
TEM
$12.4B
$2.07M 0.43%
+35,000
New +$2.74M
2025 Q4
0 quarters
TBI icon
36
Trueblue
TBI
$269M
$2.01M 0.42%
442,554
+363,078
+457% +$1.86M
2025 Q3
1 quarter
PLRX icon
37
Pliant Therapeutics
PLRX
$59.9M
$1.9M 0.39%
1,555,744
+1,535,257
+7,494% +$2.31M
2025 Q1
3 quarters
RNTX icon
38
Rein Therapeutics
RNTX
$65.1M
$513K 0.11%
442,600
-125,298
-22% -$173K
2024 Q2
6 quarters
ACHC icon
39
Acadia Healthcare
ACHC
$2.81B
– –
-250,000
Closed -$6.19M –
AKRO icon
40
DELISTED
Akero Therapeutics
AKRO
– –
-39,072
Closed -$1.86M –
ALGN icon
41
Align Technology
ALGN
$10.2B
– –
-19,442
Closed -$2.43M –
ARGX icon
42
argenx
ARGX
$50.5B
– –
-3,300
Closed -$2.43M –
BHVN icon
43
Biohaven
BHVN
$1.72B
– –
-600,000
Closed -$9.01M –
CORT icon
44
CALL
Corcept Therapeutics
CORT
$12.7B
– –
-147,800
Closed -$12.3M –
CTMX icon
45
CytomX Therapeutics
CTMX
$508M
– –
-564,800
Closed -$1.8M –
DXCM icon
46
DexCom
DXCM
$32.1B
– –
-195,217
Closed -$13.1M –
ISRG icon
47
Intuitive Surgical
ISRG
$149B
– –
-48,711
Closed -$21.8M –
PRTA icon
48
Prothena Corp
PRTA
$429M
– –
-20,000
Closed -$195K –
SDGR icon
49
Schrodinger
SDGR
$1.94B
– –
-34,830
Closed -$699K –
SGHT icon
50
Sight Sciences
SGHT
$462M
– –
-439,941
Closed -$1.51M –
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q4 2025 Portfolio in Review

As of Q4 2025, Prosight Management held 53 positions worth $484M, up 13% from $429M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Prosight Management deployed $73.1M of net new capital in Q4 2025, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 554,633 shares worth $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $15.4M trimmed.

  • Prosight Management's largest Q4 2025 buy was Nektar Therapeutics: 554,633 shares worth $23.4M.
  • Prosight Management added most to Procept Biorobotics in Q4 2025, an estimated $43.2M increase.
  • Prosight Management's biggest Q4 2025 reduction was BridgeBio Pharma, cutting an estimated $15.4M.
  • Prosight Management fully exited Intuitive Surgical in Q4 2025, selling an estimated $21.8M.
  • Prosight Management's ten largest holdings make up 57% of its $484M portfolio in Q4 2025.
  • Prosight Management opened 11 new positions and closed 15 in Q4 2025.
  • Prosight Management's portfolio value rose 13% quarter-over-quarter to $484M.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.